The Latest Breaking News from BMY

The rising prevalence of chronic diseases and the aging population are major growth drivers for the healthcare industry. In addition, increased investments in technological advancements should further bolster the industry’s growth. Thus, we think it may be prudent to buy quality healthcare stocks Pfizer Inc. (PFE), Merck & Co. (MRK),…

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 10 strange trades.

Persistent rate hikes by the Fed and rising odds of a recession have aggravated market turbulence and led investors to seek refuge in defensive sectors such as healthcare. Defensive stocks tend to perform well in declining markets due to the steady demand for their products. Hence, consistent dividend-yielding drug stocks…

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Recession odds are rising due to the onslaught of aggressive rate hikes by the Fed. Healthcare is conventionally considered a defensive sector. Hence, we think Johnson & Johnson (JNJ), AbbVie (ABBV), and Bristol-Myers Squibb (BMY) might be solid buys now. Read on….

Blood thinners produced by drug giants Bristol Myers and Bayer fell short of predictions, leading shares of both stocks down Monday.

The U.S. market came back in July and early August owing to a robust job market, strong corporate earnings, and a slight decline in inflation. However, the Fed’s hawkish stance to hike the interest rates aggressively until inflation comes down to the target level is expected to keep the market…

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Substantial investments in R&D, an aging population, and growing demand for advanced drugs to treat chronic diseases should drive the pharmaceutical industry’s growth. Therefore, investing in fundamentally strong and dividend-paying pharma stocks Johnson & Johnson (JNJ) and Bristol-Myers Squibb (BMY) could help dodge the current market volatility and generate substantial…